Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New supplement shows promise for stronger muscles in seniors

NCT ID NCT07402278

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily supplement called HB05P can safely improve muscle strength in adults aged 60 to 79 who have age-related muscle weakness. Eighty participants took either HB05P or a placebo for 12 weeks, and everyone did regular walking and resistance exercises. The main goal was to measure changes in leg muscle strength using a special machine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 60 years or older and younger than 80 years (male or female) who meet the inclusion criteria and do not meet any exclusion criteria * Body Mass Index (BMI) between 18.5 and 30.0 kg/m² * Skeletal muscle mass less than 110% of standard value measured by Bioelectrical Impedance Analysis (BIA) * Reduced handgrip strength in the dominant hand based on age- and sex-specific criteria: (Ages 60-69) Males ≤38.5 kg, Females ≤24.1 kg; (Ages 70-79) Males ≤33.2 kg, Females ≤20.9 kg * Capable of normal physical activity and voluntarily providing written informed consent to participate in this study Exclusion Criteria: * History of bone fracture within the past 1 year * Serum creatinine greater than 2 times the upper limit of normal at the study site * AST (GOT) or ALT (GPT) greater than 2 times the upper limit of normal at the study site * Current diabetes mellitus or fasting blood glucose ≥126 mg/dL * Uncontrolled hyperthyroidism or hypothyroidism * Uncontrolled hypertension (blood pressure ≥160/100 mmHg) * Currently taking medication for psychiatric disorders (except for intermittent use for sleep disorders) * Participation in another drug clinical trial within 1 month prior to screening * Regular consumption (≥4 times/week) of probiotics or fermented dairy products (yogurt, cheese, etc.) within 2 weeks prior to screening * Use of medications or health functional foods related to muscle function within 1 month prior to screening (refer to prohibited concomitant medications) * History of gastrointestinal resection surgery (except appendectomy) * Pregnant or lactating women, or women planning to become pregnant during the study period * Known allergy to any component of the study product * History of alcohol abuse * Asthma or obstructive/restrictive pulmonary disease that may affect lung volume * Uncooperative attitude or any condition that, in the investigator's judgment, would make the participant unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related muscle weakness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chung-Ang University Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.